CVie Therapeutics Limited
Tainan
About CVie Therapeutics Limited
CVie Therapeutics Limited is a Taiwan-based joint venture founded in 2013 by Lee's Pharmaceutical Holdings Limited and renowned venture capitals from the US and Taiwan. It is a stand-alone drug development company specialized in cardiovascular diseases. CVie currently owns two phase IIb assets that target cardiovascular diseases with significant unmet medical need. Rostafuroxin is a novel precision medicine targeting hypertensive patients with certain genetic profiles with better efficacy and safety than conventional therapies. Istaroxime is a first-in-class luso-inotropic medicine for the treatment of acute heart failure and will have fewer adverse effects than conventional inotropes, namely, increased heart rate, arrhythmia, increased oxygen consumption, hypotension, etc.YEAR FOUNDED:
2013
LEADERSHIP:
CEO: Dr. Benjamin Li
COO: Lit-Fui Lau
2 articles about CVie Therapeutics Limited
-
Windtree Therapeutics and CVie Therapeutics Announce Merger to Create a Global Acute Care Company Targeting Cardiovascular and Respiratory Diseases
12/21/2018
Windtree Also Completes $39.0 Million Private Placement of Common Stock and Warrants
-
ScinoPharm And CVie Therapeutics Limited To Jointly Develop New Heart Failure Drug
8/5/2016